4//SEC Filing
Hardie Robert D. 4
Accession 0001209191-21-046028
CIK 0001576885other
Filed
Jul 7, 8:00 PM ET
Accepted
Jul 8, 6:15 PM ET
Size
16.0 KB
Accession
0001209191-21-046028
Insider Transaction Report
Form 4
Hardie Robert D.
10% Owner
Transactions
- Conversion
Series A-1 Preferred Stock
2021-07-06−1,634,515→ 0 total(indirect: See footnote)→ Common Stock (1,634,515 underlying) - Conversion
Series B Preferred Stock
2021-07-06−1,315,969→ 0 total(indirect: See footnote)→ Common Stock (1,315,969 underlying) - Purchase
Common Stock
2021-07-06$16.00/sh+312,500$5,000,000→ 3,352,693 total(indirect: See footnote) - Conversion
Common Stock
2021-07-06+657,985→ 657,985 total(indirect: See footnote) - Conversion
Common Stock
2021-07-06+2,950,484→ 3,040,193 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-07-06−657,985→ 0 total(indirect: See footnote)→ Common Stock (657,985 underlying)
Footnotes (3)
- [F1]On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F2]The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
- [F3]The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
Documents
Issuer
Acumen Pharmaceuticals, Inc.
CIK 0001576885
Entity typeother
Related Parties
1- filerCIK 0001804350
Filing Metadata
- Form type
- 4
- Filed
- Jul 7, 8:00 PM ET
- Accepted
- Jul 8, 6:15 PM ET
- Size
- 16.0 KB